Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Sells $29,310.00 in Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper sold 977 shares of the company’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the transaction, the chief financial officer now directly owns 164,269 shares in the company, valued at approximately $4,928,070. The trade was a 0.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Colleen Tupper also recently made the following trade(s):

• On Tuesday, March 11th, Colleen Tupper sold 10,445 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $30.01, for a total value of $313,454.45.
• On Thursday, March 6th, Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $30.00, for a total value of $58,470.00.

Collegium Pharmaceutical Stock Up 0.3 %

Shares of COLL stock opened at $29.93 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a twelve month low of $27.28 and a twelve month high of $42.29. The stock has a 50 day moving average of $30.75 and a 200 day moving average of $32.77. The stock has a market cap of $942.38 million, a P/E ratio of 12.90 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. As a group, sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in shares of Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after purchasing an additional 175,892 shares in the last quarter. Penserra Capital Management LLC acquired a new stake in Collegium Pharmaceutical in the third quarter valued at approximately $757,000. Barclays PLC increased its position in shares of Collegium Pharmaceutical by 152.2% in the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock valued at $2,899,000 after buying an additional 45,291 shares in the last quarter. Sanctuary Advisors LLC raised its stake in shares of Collegium Pharmaceutical by 10.7% during the 3rd quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock worth $695,000 after buying an additional 1,731 shares during the period. Finally, FMR LLC raised its stake in shares of Collegium Pharmaceutical by 1,532.2% during the 3rd quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock worth $1,459,000 after buying an additional 35,439 shares during the period.

Analyst Ratings Changes

Several equities analysts recently weighed in on COLL shares. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a report on Friday, January 10th. Piper Sandler dropped their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.